SGLT2 inhibitors attenuate nephrin loss and enhance TGF-β1 secretion in type 2 diabetes patients with albuminuria: a randomized clinical trial

SGLT2 inhibitors attenuate nephrin loss and enhance TGF-β1 secretion in type 2 diabetes patients with albuminuria: a randomized clinical trial

Abstract To evaluate the effect of SGLT2 inhibitor (SGLT2i) on albuminuria, nephrin (NPH) and transforming-growth-factor-beta1 (TGF-β1) levels in urine and low-grade inflammation in type 2 diabetes (T2D) patients. A randomized, blank-controlled clinical trial included 68 T2D patients and 10 controls...

Full description

Bibliographic Details
Main Authors:	Yuan Tian, Xiao-min Chen, Xian-ming Liang, Xiao-bin Wu, Chun-meng Yao
Format:	Article
Language:	English
Published:	Nature Portfolio 2022-09-01
Series:	Scientific Reports
Online Access:	https://doi.org/10.1038/s41598-022-19988-7

Similar Items

Glycosphingolipid GM3 prevents albuminuria and podocytopathy induced by anti-nephrin antibody
by: Nagako Kawashima, et al.
Published: (2022-09-01)

Correlation between albuminuria and interstitial injury marker reductions associated with SGLT2 inhibitor treatment in diabetic patients with renal dysfunction
by: Saeko Sato, et al.
Published: (2022-08-01)

Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury.
by: Yoon-Kyung Chang, et al.
Published: (2016-01-01)

Renoprotective potential of concomittant medications with SGLT2 inhibitors and renin-angiotensin system inhibitors in diabetic nephropathy without albuminuria: a retrospective cohort study
by: Tatsuya Ishibashi, et al.
Published: (2023-09-01)

SGLT2 Inhibitors for Cardioprotection
by: Sulthan Al Rashid, et al.
Published: (2023-07-01)

Multivariate Statistical Approach for Nephrines in Women with Obesity
by: Ralitsa Robeva, et al.
Published: (2021-03-01)

Shenkang protects renal function in diabetic rats by preserving nephrin expression
by: Zhihui Qu, et al.
Published: (2023-07-01)

Electrocardiographic changes associated with SGLT2 inhibitors and non-SGLT2 inhibitors: A multi-center retrospective study
by: Victor Chien-Chia Wu, et al.
Published: (2022-09-01)

Neuroprotective Effect of SGLT2 Inhibitors
by: Agnieszka Pawlos, et al.
Published: (2021-11-01)

SGLT2 Inhibitors and Their Antiarrhythmic Properties
by: Ewald Kolesnik, et al.
Published: (2022-01-01)

Benefits of SGLT2 inhibitors in arrhythmias
by: Jinghan Gao, et al.
Published: (2022-10-01)

Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure
by: Sok Cin Tye, et al.
Published: (2022-09-01)

Integrin Ligation Results in Nephrin Tyrosine Phosphorylation In Vitro.
by: Rakesh Verma, et al.
Published: (2016-01-01)

Is cancer incidence modified by SGLT2 inhibitors?
by: Lev M. Berstein
Published: (2019-10-01)

SGLT2 inhibitors: Beyond glycemic control
by: Irtiza Hasan, et al.
Published: (2024-03-01)

The Effects of SGLT2 Inhibitors on Lipid Metabolism
by: Zsolt Szekeres, et al.
Published: (2021-02-01)

SGLT2 Inhibitors as Potential Anticancer Agents
by: Debasish Basak, et al.
Published: (2023-06-01)

Antioxidant Roles of SGLT2 Inhibitors in the Kidney
by: Carmen Llorens-Cebrià, et al.
Published: (2022-01-01)

SGLT-2 inhibitors and their potential in the treatment of diabetes
by: Rosenwasser RF, et al.
Published: (2013-11-01)

Possible renoprotective mechanisms of SGLT2 inhibitors
by: Akira Nishiyama, et al.
Published: (2023-03-01)

Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
by: Zofia Wicik, et al.
Published: (2022-08-01)

Effects of SGLT2 Inhibitors beyond Glycemic Control—Focus on Myocardial SGLT1
by: Alex Ali Sayour, et al.
Published: (2021-09-01)

The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure
by: Peng‐juan Ji, et al.
Published: (2023-04-01)

SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?
by: Yoshifumi Saisho
Published: (2020-05-01)

Targeting high glucose-induced epigenetic modifications at cardiac level: the role of SGLT2 and SGLT2 inhibitors
by: Lucia Scisciola, et al.
Published: (2023-02-01)

SGLT2i relieve proteinuria in diabetic nephropathy patients potentially by inhibiting renal oxidative stress rather than through AGEs pathway
by: Xiao-chun Zeng, et al.
Published: (2024-02-01)

TGF-β1 Receptor Inhibitor SB525334 Attenuates the Epithelial to Mesenchymal Transition of Peritoneal Mesothelial Cells via the TGF-β1 Signaling Pathway
by: Jung-Yoon Heo, et al.
Published: (2021-07-01)

Mechanistic evaluation of the inhibitory effect of four SGLT-2 inhibitors on SGLT 1 and SGLT 2 using physiologically based pharmacokinetic (PBPK) modeling approaches
by: Yu Zhang, et al.
Published: (2023-06-01)

Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases
by: Kai-Fan Tsai, et al.
Published: (2021-07-01)

SHP2 inhibitors maintain TGFβ signalling through SMURF2 inhibition
by: Xianning Lai, et al.
Published: (2023-12-01)

Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis
by: Lubin Xu, et al.
Published: (2017-06-01)

Urinary Nephrin is a Sensitive Marker to Predict Early Onset of Nephropathy in Type 2 Diabetes Mellitus
by: Ganesh Veluri, et al.
Published: (2022-12-01)

Nephrin regulates lamellipodia formation by assembling a protein complex that includes Ship2, filamin and lamellipodin.
by: Madhusudan Venkatareddy, et al.
Published: (2011-01-01)

SGLT2 inhibitors: control of glycemia and nephroprotection properties
by: A. A. Volodin, et al.
Published: (2018-02-01)

SGLT2 inhibitors and the cardiac rhythm: unraveling the connections
by: Aritra Paul, et al.
Published: (2024-01-01)

An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
by: Teresa Salvatore, et al.
Published: (2022-03-01)

SGLT-2 inhibitors: Post infarction interventional effects
by: Pugazhenthan Thangaraju, et al.
Published: (2023-03-01)

The Ketogenic Effect of SGLT-2 Inhibitors—Beneficial or Harmful?
by: Michail Koutentakis, et al.
Published: (2023-11-01)

Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection
by: Yi-Chou Hou, et al.
Published: (2020-10-01)

Cardiovascular Diseases: Therapeutic Potential of SGLT-2 Inhibitors
by: Weronika Frąk, et al.
Published: (2023-07-01)